In the COLCOT trial, which involved 4,745 patients with a recent MI, those who were randomized to 0.5 mg colchicine daily experienced a significantly lower risk of ischemic CV events compared with those who took placebo. After a median 22.6 months of follow-up, the composite endpoint of CV-related death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina leading to coronary revascularization occurred in 5.5% of the colchicine group vs. 7.1% of the placebo group (hazard ratio, 0.77). Adverse events, including diarrhea, were similar between groups.
Like what you just read ? Let us now